Small molecule-switchable RNA platform enables control of therapeutic protein expression

FHS
January 2, 2024
11:27 am

Just like a doctor adjusts the dose of a medication to the patient’s needs, the expression of therapeutic genes, those modified in a person to treat or cure a disease via gene therapy, also needs to be maintained within a therapeutic window.

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy – Pharmaceutical Technology

DMD is a rare, progressive genetic disorder characterised by the degeneration and weakness of muscles. Credit: Raja GamerXTC via Shutterstock. RegenxBio has revealed plans to

November 19, 2024

PicnicHealth Launches Clinical Services to Enhance Care Management

What You Should Know: – PicnicHealth, a pioneer in real-world data (RWD) and clinical AI has unveiled its new Clinical Services division, featuring a Virtual

September 25, 2024

70% of People with Diabetes Feel Stigma: Abbott Survey Reveals

[embedded content] What You Should Know: – A recent survey and film conducted by Abbott reveals the significant impact of stigma and misconceptions on people

February 5, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.